Clinical Trial Update: Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

View source ↗

Summary

A completed clinical trial reports switching to degarelix after GnRH agonist failure in hormone-sensitive prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Firmagon (Degarelix)

Snippet

Sponsor: CMX Research | Conditions: Prostate Cancer | Status: COMPLETED